NERM
ARCT icon

New England Research & Management’s Arcturus Therapeutics ARCT Stock Holding History

New England Research & Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-6,005
Closed -$248K – 172
2021
Q1 		$248K Buy
+6,005
New +$358K 0.14% 155

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

New England Research & Management's ARCT Position: Q2 2021 in Review

New England Research & Management sold out of Arcturus Therapeutics (ARCT) in Q2 2021, closing a stake of 6,005 shares — an estimated $248K sold.

New England Research & Management first reported a position in ARCT in Q1 2021 and held it in 1 quarter. The position peaked at $248K in Q1 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q2 2021.

  • New England Research & Management reported no remaining Arcturus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • New England Research & Management sold 6,005 Arcturus Therapeutics shares in Q2 2021, an estimated $248K.
  • New England Research & Management first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 1 quarter.
  • New England Research & Management's Arcturus Therapeutics position peaked at $248K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2021.

Based on New England Research & Management's 13F filing for Q2 2021, filed 15 Jul 2021.